GBA1 and Parkinson disease: Questions to be discussed are at which stage of the disease PD patients with GBA mutations would be amenable to treatment with a compound targeting a GBA-based mechanism, as well as whether there may be additional pathophysiological aspects to be discovered that add to the development of the disease in PD patients with a GBA mutation.